

David L Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6115298/publications.pdf>

Version: 2024-02-01

54
papers

751
citations

623734

14
h-index

580821

25
g-index

55
all docs

55
docs citations

55
times ranked

1154
citing authors

#	ARTICLE	IF	CITATIONS
1	Computed tomography (CT)-defined sarcopenia and myosteatosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT). <i>European Journal of Clinical Nutrition</i> , 2022, 76, 143-149.	2.9	8
2	Letter to Editor Re: "Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms" (https://doi.org/10.1016/j.acra.2021.10.004). <i>Academic Radiology</i> , 2022, , .	2.5	0
3	Outcome of patient with myasthenia gravis with the use of immunotherapy in metastatic Merkel cell carcinoma. <i>Oxford Medical Case Reports</i> , 2022, 2022, omac012.	0.4	1
4	Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review. <i>World Journal of Nuclear Medicine</i> , 2021, 20, 329-335.	0.5	9
5	Succinate dehydrogenase-deficient gastrointestinal stromal tumor: from diagnostic dilemma to novel personalised therapy in 2 case reports. <i>Translational Cancer Research</i> , 2021, 10, 0-0.	1.0	6
6	Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1278-1284.	5.0	25
7	Real-world management and patient perspectives on QOL with neuroendocrine tumors: An ANZ perspective. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 3-10.	1.1	1
8	Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	1.1	0
9	Marked improvement in hyperammonaemic encephalopathy from multimodal treatment of metastatic neuroendocrine tumour. <i>BMJ Case Reports</i> , 2021, 14, e241191.	0.5	2
10	Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. <i>Oncologist</i> , 2021, 26, 950-955.	3.7	19
11	A pilot study of everolimus and radiation for neuroendocrine liver metastases. <i>Endocrine-Related Cancer</i> , 2021, 28, 541-548.	3.1	4
12	Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2543-2550.	1.0	8
13	Life-threatening diarrhea in neuroendocrine tumors: two case reports. <i>Journal of Medical Case Reports</i> , 2021, 15, 542.	0.8	2
14	Are We Choosing Surveillance Imaging in Gastric and Pancreatic Cancers Wisely? A Population-Based Study. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 189-195.	1.3	2
15	High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2020, 110, 950-958.	2.5	19
16	The Virtual Neurologic Exam: Instructional Videos and Guidance for the COVID-19 Era. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 598-603.	0.5	66
17	Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases. <i>Pathology</i> , 2020, 52, 515-521.	0.6	5
18	Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 237.	2.8	22

#	ARTICLE	IF	CITATIONS
19	Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1539-1542.	1.0	6
20	Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours. <i>Oncotarget</i> , 2020, 11, 2636-2646.	1.8	8
21	Systemic Therapy for Neuroendocrine Neoplasms. <i>Digestive Disease Interventions</i> , 2019, 03, 063-070.	0.2	0
22	External Beam Radiotherapy in the Treatment of Gastroenteropancreatic Neuroendocrine Tumours: A Systematic Review. <i>Clinical Oncology</i> , 2018, 30, 400-408.	1.4	25
23	Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2018, 4, 583.	7.1	49
24	Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS). <i>Neuroendocrinology</i> , 2018, 107, 32-41.	2.5	10
25	Utilizing 18F-fluoroethyl-L-tyrosine positron emission tomography in high grade glioma for radiation treatment planning in patients with contraindications to MRI. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 122-127.	1.8	8
26	Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 256-263.	1.1	8
27	Small Bowel Neuroendocrine Tumors: Big Advances in the Land of Small Tumors. <i>Journal of Oncology Practice</i> , 2018, 14, 485-486.	2.5	0
28	New drug developments in metastatic gastric cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880807.	3.2	19
29	FET PET in the evaluation of indeterminate brain lesions on MRI: Differentiating glioma from other non-neoplastic causes – A pilot study. <i>Journal of Clinical Neuroscience</i> , 2018, 58, 130-135.	1.5	3
30	Developments in the treatment of carcinoid syndrome – impact of telotristat. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 323-329.	2.0	6
31	Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2018, 4, 1597.	7.1	68
32	Current Chemotherapy Use in Neuroendocrine Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 603-614.	3.2	12
33	Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2017, 104, 209-222.	2.5	13
34	Prognostic and predictive biomarkers in neuroendocrine tumours. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 268-282.	4.4	42
35	Principles of diagnosis and management of neuroendocrine tumours. <i>Cmaj</i> , 2017, 189, E398-E404.	2.0	66
36	Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. <i>Endocrine</i> , 2017, 57, 366-375.	2.3	33

#	ARTICLE	IF	CITATIONS
37	Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration. <i>Journal of Global Oncology</i> , 2017, 3, 380-388.	0.5	6
38	The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0172307.	2.5	11
39	Escalated dose somatostatin analogues (SSAs) in management of neuroendocrine tumors (NETs): A systematic review.. <i>Journal of Clinical Oncology</i> , 2017, 35, 422-422.	1.6	0
40	Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). <i>PLoS ONE</i> , 2016, 11, e0158140.	2.5	22
41	Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. <i>Cancer Treatment Reviews</i> , 2016, 47, 32-45.	7.7	74
42	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <i>Lung Cancer</i> , 2016, 102, 21-27.	2.0	11
43	Prognostic utility of tumour infiltrating lymphocytes (TILs) and neutrophil-to-lymphocyte ratio (NLR) in early-stage triple negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 1075-1075.	1.6	1
44	The lymphocyte-to-monocyte ratio as a predictor of overall survival in comparison to established systemic markers of inflammation in resectable colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 593-593.	1.6	1
45	Adjuvant therapy in pancreatic adenocarcinoma: A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 330-330.	1.6	0
46	Change in inflammatory status as a prognostic marker of overall survival in colorectal patients undergoing resection.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6571-6571.	1.6	0
47	Malignant Cardiac Tamponade from Non-Small Cell Lung Cancer: Case Series from the Era of Molecular Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2015, 4, 75-84.	2.4	14
48	Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. <i>PLoS ONE</i> , 2015, 10, e0135599.	2.5	22
49	Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report. <i>Molecular and Clinical Oncology</i> , 2015, 3, 817-819.	1.0	10
50	Antiangiogenic agents (AAs) in metastatic oesophago-gastric cancer (mOGC): A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15111-e15111.	1.6	1
51	Pretreatment neutrophil/lymphocyte ratio (NLR) prior to steroids as a prognostic factor in metastatic castrate refractory prostate cancer (mCRPC) patients treated with taxanes.. <i>Journal of Clinical Oncology</i> , 2015, 33, 273-273.	1.6	0
52	Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction. <i>Oxford Medical Case Reports</i> , 2014, 2014, 105-106.	0.4	0
53	Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal cancer (mCRC): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3552-3552.	1.6	2
54	Meta-analysis of outcomes of VEGF and EGFR targeted biologic therapy in relapsed metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 534-534.	1.6	1